This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
broker-rating: Archive
Is ARKO (ARKO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for ARKO (ARKO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ARKOPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Duolingo (DUOL) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Duolingo (DUOL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
DUOLNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Comcast (CMCSA) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Comcast (CMCSA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CMCSANegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Deckers (DECK) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Deckers (DECK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DECKPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Lilly (LLY) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
LLYNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Uranium Energy (UEC) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Uranium Energy (UEC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
UECPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ADMANegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in SharkNinja, Inc. (SN) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in SharkNinja, Inc. (SN). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
SNPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is VALE (VALE) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for VALE (VALE) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VALEPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Blue Bird (BLBD): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Blue Bird (BLBD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
BLBDNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
SkyWest (SKYW) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in SkyWest (SKYW). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
SKYWNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think Sensus Healthcare (SRTS) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Sensus Healthcare (SRTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
SRTSNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Workday (WDAY) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Workday (WDAY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
WDAYNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About PulteGroup (PHM): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), PulteGroup (PHM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
PHMNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is AppLovin (APP) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for AppLovin (APP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
APPPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Kroger (KR) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Kroger (KR) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
KRNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is High Tide (HITI) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), High Tide (HITI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
HITIPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See ACM Research (ACMR) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for ACM Research (ACMR) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ACMRNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Arista Networks (ANET) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Arista Networks (ANET) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ANETPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in MPLX LP (MPLX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for MPLX LP (MPLX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MPLXPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
MCKNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About Sunrun (RUN): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Sunrun (RUN). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
RUNPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in General Motors (GM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in General Motors (GM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
GMPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Vital Farms (VITL) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Vital Farms (VITL) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VITLNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About SentinelOne (S): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for SentinelOne (S) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth